Acorn Financial Advisory Services Inc. ADV Purchases Shares of 945 IQVIA Holdings Inc. (NYSE:IQV)

Acorn Financial Advisory Services Inc. ADV acquired a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 945 shares of the medical research company’s stock, valued at approximately $224,000.

Several other institutional investors also recently modified their holdings of IQV. Versant Capital Management Inc increased its holdings in shares of IQVIA by 733.3% in the second quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock valued at $26,000 after purchasing an additional 110 shares during the last quarter. Opal Wealth Advisors LLC bought a new position in IQVIA in the 2nd quarter valued at about $27,000. Capital Performance Advisors LLP bought a new stake in shares of IQVIA during the third quarter worth approximately $27,000. Park Place Capital Corp acquired a new position in shares of IQVIA in the third quarter valued at approximately $28,000. Finally, Itau Unibanco Holding S.A. bought a new position in shares of IQVIA during the second quarter worth approximately $29,000. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on IQV. StockNews.com downgraded IQVIA from a “buy” rating to a “hold” rating in a report on Friday. The Goldman Sachs Group dropped their price objective on shares of IQVIA from $280.00 to $250.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Redburn Atlantic assumed coverage on shares of IQVIA in a research report on Monday, October 14th. They set a “buy” rating and a $276.00 target price on the stock. Barclays dropped their price target on shares of IQVIA from $260.00 to $255.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. Finally, UBS Group increased their price target on IQVIA from $295.00 to $300.00 and gave the stock a “buy” rating in a research report on Tuesday, July 23rd. Five equities research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $259.13.

Insider Buying and Selling at IQVIA

In other news, insider Eric Sherbet sold 1,300 shares of the company’s stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total value of $320,229.00. Following the completion of the transaction, the insider now owns 19,536 shares of the company’s stock, valued at $4,812,302.88. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Corporate insiders own 1.60% of the company’s stock.

IQVIA Price Performance

Shares of IQV traded up $1.55 during trading hours on Friday, reaching $219.23. The stock had a trading volume of 1,418,430 shares, compared to its average volume of 1,101,442. The stock has a market capitalization of $39.79 billion, a PE ratio of 28.76, a PEG ratio of 2.26 and a beta of 1.51. IQVIA Holdings Inc. has a 12 month low of $190.20 and a 12 month high of $261.73. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81. The company’s 50-day moving average is $231.00 and its two-hundred day moving average is $229.31.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.